Institut de Recherche pour le Developpement

Quick facts

Marketed products

• Chloroquine profilaxis · Infectious Disease
  Chloroquine inhibits parasite growth by accumulating in parasite food vacuoles and interfering with heme detoxification and nucleic acid synthesis.

Phase 3 pipeline

• Anti-HBV antiviral prophylaxis · Infectious Disease / Virology
  Anti-HBV antiviral prophylaxis prevents hepatitis B virus infection or reactivation by inhibiting viral replication through antiviral mechanisms.
• Gatifloxacin combined regimen · Infectious Disease
  Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
• Nevirapine, zidovudine, lamivudine · Infectious Disease / Virology
  This combination of three antiretroviral drugs inhibits HIV reverse transcriptase and non-nucleoside reverse transcriptase to suppress viral replication.
• sulfadoxine-pyrimethamine / mefloquine · Infectious Diseases
  Sulfadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while mefloquine is a blood schizonticide.

Phase 2 pipeline

• Creatinina · Other
• Praziquantel 600 milligram

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Institut de Recherche pour le Developpement portfolio CI brief
• Institut de Recherche pour le Developpement pipeline updates RSS